Previous 10 | Next 10 |
Bristol-Myers Receives FDA Approval for Celgene’s Ozanimod Bristol-Myers Squibb ( BMY ) (BMYMP) announced that it has received the FDA approval for Ozanimod, an MS drug it acquired through its purchase of Celgene business. The approval comes after quite a few roadblocks including ...
Citing clinical trial sites' urgent shift towards fighting the COVID-19 pandemic, AVEO Oncology (NASDAQ: AVEO ) and collaboration partner Biodesix have decided to terminate a Phase 2 study evaluating ficlatuzumab (AV-299), combined with high-dose cytarabine, in patients with relapsed/ref...
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cyta...
AVEO Pharmaceuticals (NASDAQ: AVEO ): Q4 GAAP EPS of -$0.28. More news on: AVEO Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. “The coming months will be an important period for AVEO, with filing of a New Drug Application (NDA) for tivozanib as a treatment for relapsed or ...
AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basi...
AVEO Oncology ( AVEO ) has had a rough go since the company announced that the FDA did not recommend they submit FOTIVDA’s NDA and will have to wait for even more mature data in mid-2020. FOTIVDA's August interim overall survival "OS" results did not assuage the FDA’s concerns ...
AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the Br...
- Data Presented at the 2020 ASCO GI Cancers Symposium - AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody pr...
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company’s financial and accounting functions. “It is a pleasure to welcome Erick to the AVEO team,” ...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...